Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.54 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | TOP1 | P11387 | 3/20 | 0.51 |
| ▸ | TOP2A | P11388 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | TERT | O14746 | 2/20 | 0.48 |
| ▸ | NPBWR1 | P48145 | 2/20 | 0.48 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.48 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.47 |
| ▸ | KDR | P35968 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | BLM | P54132 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | SLCO2B1 | O94956 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14669420 | 0.99 | MAPT (0.53) | MAPTSIRT6ALDH1A1SMN1; SMN2TOP1 | |
| SCHEMBL14892358 | 0.96 | MAPT (0.50) | MAPTSIRT6ALDH1A1SMN1; SMN2TOP1 | |
| SCHEMBL12288111 | 0.89 | NPBWR1 (0.46) | MAPTSIRT6ALDH1A1SMN1; SMN2TOP1 | |
| SCHEMBL10070212 | 0.89 | MAPT (0.55) | MAPTSIRT6ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL14906660 | 0.89 | ALDH1A1 (0.57) | MAPTSIRT6ALDH1A1SMN1; SMN2TOP1 | |
| SCHEMBL12286566 | 0.88 | TERT (0.48) | MAPTSIRT6ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL12287148 | 0.88 | NPBWR1 (0.48) | MAPTSIRT6ALDH1A1SMN1; SMN2TOP1 | |
| SCHEMBL14892447 | 0.88 | NPBWR1 (0.51) | MAPTALDH1A1SMN1; SMN2TERTNPBWR1 | |
| SCHEMBL12286935 | 0.88 | MAPT (0.53) | MAPTSIRT6ALDH1A1SMN1; SMN2TOP1 | |
| SCHEMBL12287010 | 0.87 | TERT (0.43) | MAPTSIRT6ALDH1A1SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1590332-B1 | A PROCESS FOR THE SYNTHESIS OF BISBENZIMIDAZOLES AND THEIR DERIVATIVES. | UNIV DELHI (IN) | 2011-04-27 | — | — | EP | claimed |
| US-RE46943-E1 | Radioprotector compounds and methods | PETER MACCALLUM CANCER INSTITUTE (AU) | 2018-07-10 | — | — | US | disclosed |
| EP-2556058-B1 | RADIOPROTECTOR COMPOUNDS AND METHODS | PETER MACCALLUM CANCER INST (AU) | 2017-06-14 | — | — | EP | disclosed |
| US-8999993-B2 | Radioprotector compounds and methods | PETER MACCALLUM CANCER INSTITUTE (AU) | 2015-04-07 | — | — | US | disclosed |
| US-20130109678-A1 | RADIOPROTECTOR COMPOUNDS AND METHODS | PETER MACCALLUM CANCER INSTITUTE (AU) | 2013-05-02 | — | — | US | disclosed |
| EP-1590332-B1 | A PROCESS FOR THE SYNTHESIS OF BISBENZIMIDAZOLES AND THEIR DERIVATIVES. | UNIV DELHI (IN) | 2011-04-27 | — | — | EP | disclosed |
| EP-2044938-A2 | Radioprotectors | Peter MacCallum Cancer Institute (AU) | 2009-04-08 | — | — | EP | disclosed |
| US-6548505-B1 | Protecting biological materials from damage caused by radiation; side effect reduction during radiotherapy or chemotherapy; indole, benzimidazole, benzoxazole or benzothiazole compounds substituted with 4-alkylpiperazino | PETER MACCALLUM CANCER INSTITUTE (AU) | 2003-04-15 | — | — | US | disclosed |
| US-6194414-B1 | CANCER THERAPY; PREVENT RADIATION DAMAGE | THE INNER AND EASTERN HEALTH CARE NETWORK (AU) | 2001-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109678-A1 | RADIOPROTECTOR COMPOUNDS AND METHODS | NR1H2, NR1H3, NR1I3 | MAPT 4678/4885SIRT6 1519/4885ALDH1A1 1707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.